Sign in

ATNM on NYSE

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is an American pharmaceutical preparations company based in Wilmington.2 Its shares trade on NYSE under the symbol ATNM.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Citius Pharmaceuticals, Inc., Incannex Healthcare Inc. or Zynerba Pharmaceuticals, or pick any stock.

  • TickerATNM on NYSE2
  • IndustryPharmaceutical Preparations2
  • HeadquartersWilmington, United States2
  • Incorporated inDE3
  • Business address100 Park Ave., 23Rd Floor, New York, Ny 100173
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300LCY1NZSXCQDT452
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O VCORP SERVICES, LLC, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 53068582

See how the biggest companies compare on our leaderboards

CAR-T and other cell therapies, with three active clinical trials currently underway.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-40274.4%Operating margin6
-37652.2%Net margin6
-432.6%Return on equity6
-$24.7MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$21.1M

Out of $90.0K in revenue.6 The company lost money this year.

Financial statements

Revenue7896$90.0K in 2025−92% since 2021
0$500.0K$1.0M$1.5M2021: $1.1M$1.1M20212022: $1.0M$1.0M2022−10%2023: $81.0K$81.0K2023−92%2025: $90.0K$90.0K2025+11%
Operating income10117896-$36.2M in 2025+64% since 2019
-$60.0M-$40.0M-$20.0M02019: -$22.1M-$22.1M20192020: -$22.4M-$22.4M2020+1%2021: -$25.0M-$25.0M2021+11%2022: -$34.1M-$34.1M2022+37%2023: -$51.9M-$51.9M2023+52%2024: -$42.1M-$42.1M2024−19%2025: -$36.2M-$36.2M2025−14%
Net income10117896-$33.9M in 2025+55% since 2019
-$60.0M-$40.0M-$20.0M02019: -$21.9M-$21.9M20192020: -$22.2M-$22.2M2020+1%2021: -$24.8M-$24.8M2021+12%2022: -$33.0M-$33.0M2022+33%2023: -$48.8M-$48.8M2023+48%2024: -$38.2M-$38.2M2024−22%2025: -$33.9M-$33.9M2025−11%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Total revenue$90.0K
Research and development, net of reimbursements$21.1M$30.0M
General and administrative$15.2M$12.1M
Total operating expenses$36.3M$42.1M
Loss from operations-$36.2M-$42.1M
Interest income net$2.4M$3.9M
Total other income$2.4M$3.9M
Net loss-$33.9M-$38.2M
Net loss per common share basic (in Dollars per share)-$1.09-$1.27
Net loss per common share diluted (in Dollars per share)-$1.09-$1.27
Weighted average common shares outstanding basic (in Shares)31.2M shares30.1M shares
Weighted average common shares outstanding diluted (in Shares)31.2M shares30.1M shares

Compare Actinium Pharmaceuticals, Inc. with another company

Corporate structure

Actinium Pharmaceuticals, Inc. sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Actinium Pharmaceuticals, Inc.

  • VANGUARD GROUP INC Filed SCHEDULE 13G/A on Actinium Pharmaceuticals, Inc., latest Jul 29, 2025 (4 filings since Nov 4, 2024)
  • BlackRock Filed SCHEDULE 13G/A on Actinium Pharmaceuticals, Inc., latest Jul 16, 2025 (2 filings since Jan 29, 2024)
  • Bigger Capital, LLC Filed SC 13G/A on Actinium Pharmaceuticals, Inc., latest Nov 8, 2024 (2 filings since Feb 9, 2024)
  • BIGGER CAPITAL FUND L P Filed SC 13G/A on Actinium Pharmaceuticals, Inc., latest Feb 6, 2023 (2 filings since Feb 9, 2022)
  • Actinium Pharmaceuticals, Inc. Wilmington, Delaware, United States
    • Actinium Pharmaceuticals Australia Pty Ltd Subsidiary · Australia

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Actinium Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Accumulated depreciation$1.1M6 Dec 31, 2025$891.0K6 Dec 31, 2024+19.4%
Property and equipment, net$295.0K6 Dec 31, 2025$364.0K6 Dec 31, 2024−19.0%
Finance-lease assets$10.0K6 Dec 31, 2025$20.0K6 Dec 31, 2024−50.0%
Operating-lease assets (leased space)$1.8M6 Dec 31, 2025$1.7M6 Dec 31, 2024+4.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$48.0M6 Dec 31, 2025$72.9M6 Dec 31, 2024−34.2%

Properties, in its own words

We do not own any real property. We have leased offices at 100 Park Avenue, New York, NY 10017, which serves as our corporate headquarters, effective June 1, 2022. The lease has a term of 5 years 2 months, with an expiration date in 2027, and a current annual rate of $636 thousand. We are also responsible for certain other costs, such as insurance, taxes, utilities and maintenance. We issued a letter of credit in connection with the lease and as of December 31, 2025, maintain a $335 thousand certified deposit as collateral for the letter of credit.

We lease lab space and office space at Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461. The lease has a term of twelve months, expiring August 31, 2026, with a current annual rate of $149 thousand. We have leased manufacturing space at the same site, effective December 1, 2025. The lease has a term of five years and one month, expiring December 31, 2030, with a current annual rate of $171 thousand.

Item 2 of the 10-K filed Mar 30, 2026.5

Leadership

Who has led Actinium Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. John Talley V.2013
  2. Sergio Traversa2013
  3. Kaushik J. Dave2013–2017
  4. Sandesh Seth2017–now

Chair

  1. Sandesh Seth2015–2019

President

  1. Diane S. Button2007
  2. John Talley V.2013
  3. Kaushik J. Dave2013–2015

Chief financial officer

  1. Enza Guagenti2013
  2. Sergio Traversa2013
  3. Kaushik J. Dave2015–2017
  4. Steve O'Loughlin2020–now

Chief operating officer

  1. Dragan Cicic2013–2015
2010201520202025
Board members and other officers (18)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Actinium Pharmaceuticals Australia Pty Ltd Australia4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Cactus Ventures, Inc.Feb 5, 2007 to Mar 29, 20133

Timeline

  1. Oct 15, 20268-K Executive or director change; Regulation FD disclosure39
  2. Aug 14, 20268-K Listing notice or transfer; Regulation FD disclosure40
  3. Jun 18, 20268-K Other events41
  4. May 29, 20268-K Listing notice or transfer; Regulation FD disclosure42
  5. Mar 26, 20268-K Shareholder vote43
  6. Feb 13, 20268-K Executive or director change44
  7. Nov 26, 20258-K Executive or director change; Shareholder vote45
  8. May 9, 20258-K Change of auditor46
  9. Nov 27, 20248-K Executive or director change; Shareholder vote47
  10. Nov 5, 20248-K Executive or director change; Other events48
  11. Aug 5, 20248-K Regulation FD disclosure49
  12. Dec 1, 20238-K Executive or director change; Shareholder vote50
  13. Jun 15, 2017New chief executive Sandesh Seth becomes CEO14
  14. Sep 18, 2013New chief executive Kaushik J. Dave becomes CEO17
  15. Aug 22, 2013New chief executive Sergio Traversa becomes CEO16
  16. Mar 20, 2013Founded Actinium Pharmaceuticals, Inc. is founded2
  17. Jan 3, 2013New chief executive John Talley V. becomes CEO15

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.16) a share, on Nov 14, 2025.51

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

100 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 20 major events, 31 insider forms, 10 large holders, 19 other. The latest 20:

  1. Oct 15, 20268-K CURRENT REPORT EDGAR
  2. Oct 9, 2026S-8 REGISTRATION STATEMENT EDGAR
  3. Sep 10, 20263 EDGAR
  4. Sep 10, 20263 EDGAR
  5. Sep 4, 20264 EDGAR
  6. Sep 4, 20264 EDGAR
  7. Sep 4, 20264 EDGAR
  8. Sep 4, 20264 EDGAR
  9. Sep 4, 20264 EDGAR
  10. Sep 4, 20264 EDGAR
  11. Aug 14, 20268-K CURRENT REPORT EDGAR
  12. Aug 7, 202610-Q QUARTERLY REPORT EDGAR
  13. Jun 18, 20268-K CURRENT REPORT EDGAR
  14. May 29, 20268-K CURRENT REPORT EDGAR
  15. May 8, 202610-Q QUARTERLY REPORT EDGAR
  16. Mar 30, 202610-K ANNUAL REPORT EDGAR
  17. Mar 26, 20268-K/A AMENDMENT NO.1 TO FORM 8-K EDGAR
  18. Feb 13, 20268-K CURRENT REPORT EDGAR
  19. Nov 26, 20258-K CURRENT REPORT EDGAR
  20. Nov 14, 202510-Q QUARTERLY REPORT EDGAR

The 100 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024Sandesh Seth61$733.2K$1.2M56
2024Steve O’Loughlin41$436.8K$581.8K56
2023Chairman and Chief Executive Officer$705.0K$4.7M56
2023Chief Financial Officer$420.0K$1.5M56

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 46. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC1,238,302$1.2M0.0%−17,214
Compass Financial Management LLC600,230$588.2K0.1%New
Millennium Management LLC514,580$504.3K0.0%−50,020
BlackRock, Inc.395,896$388.0K0.0%+24,686
Renaissance Technologies LLC380,491$372.9K0.0%−91,109
Geode Capital Management, LLC324,945$318.6K0.0%−11,128
Two Sigma Investments, LP259,179$254.0K0.0%−77,989
Gagnon Securities LLC182,142$178.5K0.0%−19,158
Vanguard Fiduciary Trust Co161,526$158.3K0.0%+1,261
State Street Corp122,215$119.8K0.0%−4,000
Gen-Wealth Partners Inc105,111$103.0K0.0%−2,000
Northern Trust Corp69,743$68.3K0.0%−6,112
Qube Research & Technologies Ltd57,812$56.7K0.0%+39,764
Susquehanna International Group, Llp56,822$55.7K0.0%−67,176
Vontobel Holding Ltd.50,000$49.0K0.0%+20,000
Bluespring Wealth Management, LLC43,000$42.1K0.0%New
Bridgeway Capital Management, LLC40,000$39.2K0.0%No change
Gerald Baker Financial Group LLC22,691$22.2K0.0%No change
Mayport, LLC22,000$21.6K0.0%No change
North Star Asset Management Inc20,000$19.6K0.0%No change
Wells Fargo & Company/mn19,800$19.4K0.0%No change
Osaic Holdings, Inc.18,865$18.5K0.0%−1,000
XTX Topco Ltd13,731$13.5K0.0%−16,479
Savvy Advisors, Inc.10,000$9.8K0.0%No change
Vanguard Global Advisers, LLC8,893$8.7K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Actinium Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARActinium Pharmaceuticals, Inc.1
  • CIK0001388320
  • Employer ID (EIN)74-29636095
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
  • Incorporated inDelaware5
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address100 Park Ave., 23Rd Floor, New York, NY 100171
  • Phone(646) 677-38701
  • Shares outstanding31,441,436 as of Aug 6, 202612
  • Public float$43.7M as of Jun 30, 20255
  • AuditorCBIZ CPAS P.C, Houston, Texas PCAOB ID 199; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceFeb 5, 20071
  • Filings507 in all: 4 (121), 8-K (105), 10-Q (56), 3 (21), 424B5 (21), 10-K (18), SC 13G/A (15), CORRESP (14)1
    All 43 form types

    UPLOAD (14), DEF 14A (13), 424B3 (10), SC 13G (9), DEFA14A (8), S-8 (7), EFFECT (6), D (5), PRE 14A (5), 10-K/A (4), 10-Q/A (4), 8-K/A (4), ARS (4), S-3 (4), SC 13D/A (4), 10QSB (3), S-1 (3), S-1/A (3), S-3/A (3), SC 13D (3), 3/A (2), DEF 14C (2), NT 10-Q (2), PRE 14C (2), SCHEDULE 13G/A (2), 10KSB (1), 10KSB/A (1), 10SB12G (1), 8-A12B (1), CERTNYS (1), D/A (1), NT 10-K (1), PRER14A (1), RW (1), SC 14F1 (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 7, 2026
    Proxy statement (DEF 14A) Nov 5, 2025
    Latest 8-K (8-K) Oct 15, 2026

Securities registered for trading

ClassSymbolExchange
Common stock, par value $0.001ATNMNYSE American

From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks Actinium Pharmaceuticals, Inc. names in Item 1A of its 10-K filed Mar 30, 2026: 63 risks under these headings, as written.5

  • Risks Related to Our Business
  • We are a clinical-stage company and have generated no revenue from commercial sales to date.
  • We have incurred net losses every year since our inception and anticipate that we will continue to incur net losses in the future.
  • If we fail to obtain additional financing, we will be unable to continue or complete our product development and you will likely lose your entire investment.
  • We have limited access to the capital markets and even if we can raise additional funding, we may be required to do so on unfavorable terms.
  • We are highly dependent on the clinical, regulatory and commercial success of ATNM-400, Actimab-A, Iomab-ACT, ATNM-400 and other pipeline candidates which we may never achieve
  • We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
  • Disruptions at the FDA and other government agencies caused by government shutdowns, leadership changes, changes to regulatory approach, layoffs, funding shortages or global health concerns could negatively impact our business
  • We may be unable to establish sales, marketing and commercial supply capabilities.
  • Our business could be adversely affected by the effects of future health epidemics.
  • Risks Related to Regulation
  • The FDA, EMA or comparable foreign regulatory authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval of our product candidates.
The other 53 risks
  • We have not demonstrated that any of our products are safe or effective for any indication and will continue to expend substantial time and resources on clinical development before any of our current or future product candidates will be eligible for FDA approval, if ever.
  • We may encounter substantial delays in our clinical trials or may not be able to conduct our trials on the timelines we expect.
  • Modifications to our product candidates may require federal approvals.
  • Clinical trials necessary to support approval of our product candidates are time-consuming and expensive.
  • Preliminary, Interim, and “top-line” data from our preclinical studies and clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • Even if our preclinical studies or early clinical trials are favorable, later clinical trials may fail to demonstrate adequately the efficacy and safety of our product candidates, which would prevent or delay regulatory approval and commercialization.
  • The intellectual property related to certain antibodies we have licensed has expired or likely expired.
  • Our Actimab-A program clinical trials are testing the same drug construct.
  • We are currently developing, and in the future may develop, product candidates in combination with other therapies and that may expose us to additional risks.
  • We may be unable to obtain a sufficient supply of isotopes to support clinical development or at commercial scale.
  • If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • FDA may take actions that would prolong, delay, suspend, or terminate clinical trials of our product candidates, which may delay or prevent us from commercializing our product candidates on a timely basis.
  • We have obtained orphan drug designation from the FDA for two of our current product candidates and intend to pursue such designation for other candidates and indications in the future, but we may be unable to obtain such designations or to maintain the benefits associated with any orphan drug designations we have received or may receive in the future.
  • Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review.
  • Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates which could limit our sales of our product candidates, if approved.
  • Healthcare legislative reform measures intended to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the regulation of the U.S. healthcare system could have a material adverse effect on our business, future revenue, if any, and results of operations.
  • Changes in the healthcare industry and in healthcare spending could adversely affect our grant funded clinical programs, business, financial condition and results of operations.
  • Our relationships with customers, health care professionals and third-party payors may be subject to applicable healthcare laws, which could expose us to penalties, including administrative, civil or criminal penalties, damages, fines, imprisonment, exclusion from participation in federal healthcare programs such as Medicare and Medicaid, reputational harm, the curtailment or restructuring of our operations and diminished future profits and earnings.
  • Third-party payors may not adequately reimburse customers for any product candidates that we may commercialize or promote and may impose coverage restrictions or limitations such as prior authorizations and step edits that affect their use.
  • Risks Related to Third Parties
  • We may rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates.
  • The protection against generic competition for our biologic drug candidates and reimbursement by CMS may be subject to future change
  • Our product candidates may never achieve market acceptance.
  • We may be subject to claims that our third-party service providers, consultants or current or former employees have wrongfully used or disclosed confidential information of third parties.
  • We currently depend on single third-party manufacturers to produce our pre-clinical and clinical trial drug supplies. Any disruption in the operations of our current third-party manufacturers, or other third-party manufacturers we may engage in the future, could adversely affect our business and results of operations.
  • If we are successful in obtaining marketing approval from the FDA and/or other regulatory agencies for any of our product candidates, we anticipate continued reliance on third-party manufacturers.
  • We may have conflicts with our partners that could delay or prevent the development or commercialization of our product candidates.
  • If in the future we are unable to establish U.S. or global sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if they are approved and we may not be able to generate any revenue.
  • We face significant competition from other biotechnology and pharmaceutical companies.
  • Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences.
  • Risks Related to Our Intellectual Property
  • We depend upon securing and protecting critical intellectual property.
  • Our patent position is highly uncertain and involves complex legal and factual questions.
  • If we are found to be infringing patents or trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license to continue the development or sale of our products, and/or pay damages.
  • Our ability to protect and enforce our patents does not guarantee that we will secure the right to commercialize our potential products and respective patents.
  • We rely on confidentiality agreements to protect our trade secrets. If these agreements are breached by our employees or other parties, our trade secrets may become known to our competitors.
  • We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
  • Obtaining and maintaining patent protection depends on compliance with various procedures and other requirements, and our patent protection could be reduced or eliminated in case of non-compliance with these requirements.
  • Risks Related to Our Operations
  • Managing our growth as we expand operations may strain our resources.
  • The use of hazardous materials, including radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subject us to liability for claims arising from the use or misuse of these materials.
  • We may undertake international operations, which will subject us to risks inherent with operations outside of the United States.
  • We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
  • We continuously evaluate our business strategy and may modify our strategy as necessary to respond to developments in our business and other factors, and any such modification such as a divestiture, spin-off, spin-out, merger or acquisition, if not successful, could have a material adverse effect on our business, financial condition, and results of operations.
  • We may expand our business through the acquisition of rights to new product candidates that could disrupt our business, harm our financial condition and may also dilute current stockholders’ ownership interests in our company.
  • Risks Related to Ownership of Our Common Stock
  • The sale of securities by us in any equity or debt financing could result in dilution to our existing stockholders and have a material adverse effect on our earnings.
  • Our common stock is subject to price volatility which could lead to losses by stockholders and potential costly security litigation.
  • We do not intend to pay dividends on our common stock, so any returns will be determined by the value of our common stock.
  • Certain provisions of our Certificate of Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to complete, even if such a transaction were in our stockholders’ interest.
  • General Risk Factors
  • We face risks associated with litigation and claims.
  • Compliance with the reporting requirements of federal securities laws can be expensive.
  • Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
  • Failure to establish and maintain adequate finance infrastructure and accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies.
  • If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the price of our common stock and trading volume could decline.
  • Our Bylaws designate the U.S. federal district courts as the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.
  • The uncertainty of tariff policies and potential countermeasures could increase our costs and disrupt our global supply chain, which could negatively impact the results of our operations.

Legal proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business.

On March 27, 2025, a putative class action complaint (the “Securities Complaint”) was filed by alleged stockholder Nitin Kohil against the Company and executives Sandesh Seth, Avinash Desai, Madhuri Vusirikala, and Sergio Giralt (the “Defendants”), styled Kohil v. Actinium Pharmaceuticals, Inc., et al., Case No. 1:25-cv-02553 in the United States District Court for the Southern District of New York, (“the Court”). The Securities Complaint alleges that the Defendants made material misrepresentations and omissions concerning the Iomab-B Phase 3 Sierra Trial during a proposed class period of October 31, 2022 to August 2, 2024 and asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Plaintiff sought unspecified damages. On June 24, 2025, the court in the securities action appointed lead plaintiffs pursuant to the Private Securities Litigation Reform Act of 1995 and re-captioned the case as In re Actinium Pharmaceuticals, Inc. Securities Litigation. Lead Plaintiffs filed an amended complaint on August 25, 2025. On October 27, 2025, Defendants moved to dismiss the amended complaint; on December 19, 2025, Lead Plaintiffs filed their opposition; and on February 2, 2026, Defendants filed their reply in support. The parties are currently awaiting the Court’s decision on Defendants’ motion

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
    SEC EDGAROther events
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56